Sorafenib
Sign in to save this workspacePrimary targets: FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
96.72
Gini
0.776
CATDS
0.023
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Sorafenib. Strongest target: RAF1 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RAF1 | 100.0% | 0.0% |
| 2 | ARAF | 100.0% | 0.0% |
| 3 | BRAF | 98.5% | 1.5% |
| 4 | HIPK4 | 98.5% | 1.5% |
| 5 | C_KIT | 98.2% | 1.8% |
| 6 | FMS | 98.1% | 1.9% |
| 7 | FLT3 | 97.3% | 2.6% |
| 8 | DDR2 | 96.3% | 3.7% |
| 9 | YSK4_MAP3K19 | 96.3% | 3.7% |
| 10 | PDGFRA | 95.6% | 4.4% |
| 11 | DDR1 | 94.2% | 5.8% |
| 12 | RET | 94.0% | 6.0% |
| 13 | MUSK | 92.0% | 8.0% |
| 14 | FLT1_VEGFR1 | 89.5% | 10.5% |
| 15 | FLT4_VEGFR3 | 87.6% | 12.4% |
| 16 | ZAK_MLTK | 86.2% | 13.8% |
| 17 | PDGFRB | 80.8% | 19.1% |
| 18 | TAOK2_TAO1 | 80.8% | 19.2% |
| 19 | ERK7_MAPK15 | 79.1% | 20.9% |
| 20 | KDR_VEGFR2 | 78.4% | 21.6% |
Selectivity landscape
Where Sorafenib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Sorafenib.
Annotations
Sign in to read and post annotations.
Loading…